Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
Your fast track through regulatory challenges With the industry facing ever increasing regulations for risk assessment, we've broadened the scope of our Emprove® portfolio and dossier structure to help you meet the latest regulatory requirements and speed your way through the regulatory maze.
Your fast track through regulatory challenges With the industry facing ever increasing regulations for risk assessment, we've broadened the scope of our Emprove® portfolio and dossier structure to help you meet the latest regulatory requirements and speed your way through the regulatory maze.
Getting the relevant information is now more convenient than ever: besides buying single dossiers, you can use the new Emprove® Suite online to find all our Emprove® Dossiers.
For drug manufacturers, complying with strict standards and ever-changing regulations is a huge challenge. Creating documentation for pharma and biopharma products can be costly and time-consuming.
Emprove® Evolve For Raw Materials: Used in Early Stages of Biopharmaceutical Manufacturing. The new Emprove® Evolve product line provides fit-for-purpose high-quality raw materials addressing applications in early stages of pharmaceutical and biopharmaceutical manufacturing such as: upstream processing, early downstream processing, clean-in-place, early synthetic steps in small molecule drug manufacture.
Enabling a More Robust Extractables and Leachables Risk Assessment extractables and potential leachables. All polymeric components such as the filters and single-use systems used in biopharmaceutical manufacturing must be assessed for safety through an evaluation of extractables and potential leachables. Extractables are compounds that can be extracted from these materials while leachables are compounds that leach from the materials into the process stream.
Emprove® Dossiers for Purification in Biomanufacturing Process High performing resins meet regulatory excellence Any component and raw material used at a later stage of the biomanufacturing process is considered a risk, as it could add a bioburden to the final drug product. While being essential, chromatography steps are often a challenge as they are highly process specific and might be present from early to late downstream. Therefore, information is crucial for manufacturers when selecting chromatography methods and products.